A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Inclusion Criteria

• Histologically or cytologically confirmed advanced malignant tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available.
• ECOG performance status of ≤ 2.
• Life expectancy of ≥ 3 months.
• The results of the laboratory tests must meet all criteria.

Exclusion Criteria

• Patients have received antitumor therapy during the first 4 weeks before study drug use.
• Received a live attenuated vaccine within 4 weeks prior to C1D1.
• Known cerebral parenchymal metastasis or meningeal metastasis.
• History of serious cardiovascular or cerebrovascular diseases.
• Active or recurrent autoimmune diseases.
• History of ascites or pleural effusion requiring drainage.
• Pregnant or lactating or planning to become pregnant at any time during the study, including the Follow-up Period.